Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France

Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004–2011: model-based estimation from two national cross-sectional serosurveys

(2016) L. LEON et al.   EPIDEMIOLOGY AND INFECTION

Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey

(2016) L. Weill-Barillet et al.   REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

(2015) Graham R. Foster et al.   GASTROENTEROLOGY

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

(2015) David R. Nelson et al.   HEPATOLOGY

Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs

(2015) Anthony Cousien et al.   HEPATOLOGY

P0745 : EQ-5D utility index in French patients with chronic hepatits C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage

(2015) M. Schwarzinger et al.   JOURNAL OF HEPATOLOGY

P0747 : Health related quality of life and utility values in chronic hepatitis C patients: A cross-sectional study in France, the Uk and Germany

(2015) S. Pol et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Eric Lawitz et al.   LANCET

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial

(2015) K Rajender Reddy et al.   LANCET INFECTIOUS DISEASES

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

(2015) Susanna Naggie et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Undiagnosed Chronically-Infected HCV Population in France. Implications for Expanded Testing Recommendations in 2014

(2015) Cécile Brouard et al.   PLoS One

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

(2014) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy

(2013) Natasha K. Martin et al.   CLINICAL INFECTIOUS DISEASES

49 LIFETIME COSTS ATTRIBUTABLE TO CHRONIC HEPATITIS C FROM THE FRENCH HEALTHCARE PERSPECTIVE (ANRS N°12188)

(2013) M. Schwarzinger et al.   JOURNAL OF HEPATOLOGY

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cycles de traitement par médicament de substitution aux opiacés dans une cohorte de patients suivis 5 ans en médecine ambulatoire

(2013) Julie Dupouy et al.   THERAPIE

Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons

(2013) Natasha K Martin et al.   BMJ Open

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence

(2011) Katy M. E. Turner et al.   ADDICTION

Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study

(2011) Anne Bukten et al.   ADDICTION

Approximate Bayesian computational methods

(2011) Jean-Michel Marin et al.   STATISTICS AND COMPUTING

HIV with contact tracing: a case study in approximate Bayesian computation

(2010) M. G. B. Blum et al.   BIOSTATISTICS

A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design

(2009) Marie Jauffret-Roustide et al.   BMC INFECTIOUS DISEASES

Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place

(2008) H. Hagan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY